CompumedicsASX:CMP +2.00%61 Days Payable is 111.87 as of Dec. 2025, which is 24% above its 10-year median of 90.29. GuruFocus rates ASX:CMP with a GF Score™ of 61/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Compumedics ranks better than 70.57% on this metric.
The historical rank and industry rank for Compumedics's Days Payable or its related term are showing as below:
ASX:CMP'
s Days Payable Range Over the Past 10 Years
Min: 70.8 Med: 90.29 Max: 130.16
Current: 115
During the past 13 years, Compumedics's highest Days Payable was 130.16. The lowest was 70.80. And the median was 90.29.
ASX:CMP's Days Payable is ranked better than 70.57% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ASX:CMP: 115.00
Compumedics's Days Payable
declined
from Dec. 2024 (128.33) to Dec. 2025 (111.87).
It may suggest that Compumedicsaccelerated paying its suppliers.
Compumedics Days Payable Related Terms
Compumedics Days Payable Historical Data
* Premium members only.
The historical data trend for Compumedics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Compumedics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Days Payable distribution charts can be found below:
* The bar in red indicates where Compumedics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Compumedics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a Days Payable of 111.87 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Compumedics and its competitors. This is 24% above median its historical median of 90.29. Over the past decade, Compumedics' Days Payable has ranged from 70.80 to 130.16. According to the industry distribution chart, Compumedics ranks #234 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 29.4%.
Is Compumedics' Days Payable too high?
Compumedics' current Days Payable of 111.87 is 24% above median its 10-year median of 90.29. Over the past 10 years, this metric has ranged from a low of 70.80 to a high of 130.16. The Medical Devices & Instruments industry median Days Payable is 67.87. Compumedics' value of 111.87 is 64.8% above this industry median. Based on the distribution chart, Compumedics ranks #234 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Compumedics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #234 out of 795 companies for Days Payable. This puts Compumedics in the upper half of its industry. The industry median Days Payable is 67.87. Compumedics' value of 111.87 is 64.8% above this benchmark. Historically, Compumedics' own Days Payable has ranged from 70.80 to 130.16 over the past decade. While the company's 10-year median is 90.29 vs. the industry median of 67.87, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Days Payable of 111.87 is 64.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Days Payable is 111.87, which is 24% above median its own 10-year median of 90.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.26 — trading 17.7% below its estimated fair value. The current Days Payable is 111.87, which is 24% above median its 10-year median of 90.29 and 64.8% above the Medical Devices & Instruments industry median of 67.87. Compumedics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Days Payable is 111.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
Days Payable: 111.87 (24% above median its 10-year median of 90.29)
GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
Industry Position: 64.8% above the Medical Devices & Instruments median (#234 of 795)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
61GF Score
Get the complete analysis for ASX:CMP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
